DrugPatentWatch Database Preview
Drugs in Development Information for GDC-0084
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for GDC-0084?
GDC-0084 is an investigational drug.
There have been 167 clinical trials for GDC-0084.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are two US patents protecting this investigational drug and forty-three international patents.
Summary for GDC-0084
| US Patents | 2 |
| International Patents | 43 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2010-07-01) |
| Vendors | 30 |
Recent Clinical Trials for GDC-0084
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential | Genentech, Inc. | Phase 1 |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Horm | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for GDC-0084
Top disease conditions for GDC-0084
Top clinical trial sponsors for GDC-0084
US Patents for GDC-0084
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GDC-0084 | Start Trial | Tricyclic PI3K inhibitor compounds and methods of use | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| GDC-0084 | Start Trial | Tricyclic PI3K inhibitor compounds and methods of use | Genentech, Inc. (South San Francisco, unknown) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GDC-0084
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GDC-0084 | Argentina | 084312 | 2030-12-16 | Start Trial |
| GDC-0084 | Australia | 2011343712 | 2030-12-16 | Start Trial |
| GDC-0084 | Australia | 2015268776 | 2030-12-16 | Start Trial |
| GDC-0084 | Brazil | 112013014914 | 2030-12-16 | Start Trial |
| GDC-0084 | Canada | 2820078 | 2030-12-16 | Start Trial |
| GDC-0084 | Chile | 2013001093 | 2030-12-16 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
